One study was reported in The New York Times (1/13/12) after being published in the British Medical Journal (1/12/12). It found that women who took a selective serotonin reuptake inhibitor (SSRI) during pregnancy were up to two times as likely to give birth to a baby with persistent pulmonary hypertension (PPH) than women who did not take an SSRI during pregnancy. Researchers analyzed birth records from Finland, Iceland, Denmark, Norway and Sweden and found that three in 1,000 births of babies exposed to an SSRI prior to birth resulted in a diagnosis of persistent pulmonary hypertension. In the general population, approximately one birth in 1,000 results in such a diagnosis.
According to researchers, the risk of having a child diagnosed with persistent pulmonary hypertension was even higher when the SSRIs were used later in the pregnancy.
READ MORE LEXAPRO LEGAL NEWS
That statement was issued before the British Medical Journal study was published.
Meanwhile, the American Academy of Pediatrics issued a policy revision on January 30, 2012, noting that infants who were exposed to SSRIs during the third trimester displayed signs such as "continuous crying, irritability, jitteriness, and/or restlessness; shivering; fever; tremors; hypertonia or rigidity; tachypnea or respiratory distress; feeding difficulty; sleep disturbance; hypoglycemia; and seizures."
According to the academy, the onset of symptoms occurred anywhere from several hours to several days after birth and usually resolved within one to two weeks. In one infant, who was reportedly exposed to Paxil, signs continued through four weeks.